mitotane has been researched along with Hypothyroidism in 4 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited." | 9.41 | Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023) |
| "Mitotane-treated patients with ACC showed low FT4, normal FT3 and TSH and impaired TSH response to TRH, characteristic of central hypothyroidism." | 7.83 | Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. ( Cannavò, S; Cotta, OR; Frasca, F; Gullo, D; Pellegriti, G; Russo, M; Scollo, C; Squatrito, S, 2016) |
| "Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited." | 5.41 | Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023) |
| "Mitotane-treated patients with ACC showed low FT4, normal FT3 and TSH and impaired TSH response to TRH, characteristic of central hypothyroidism." | 3.83 | Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. ( Cannavò, S; Cotta, OR; Frasca, F; Gullo, D; Pellegriti, G; Russo, M; Scollo, C; Squatrito, S, 2016) |
| "Mitotane toxicity was graded using NCI CTCAE criteria." | 1.35 | Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. ( Angeli, A; Aroasio, E; Berruti, A; Daffara, F; De Francia, S; Di Carlo, F; Dogliotti, L; Porpiglia, F; Reimondo, G; Termine, A; Terzolo, M; Volante, M; Zaggia, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Poirier, J | 1 |
| Godemel, S | 1 |
| Mourot, A | 1 |
| Grunenwald, S | 1 |
| Olney, HJ | 1 |
| Le, XK | 1 |
| Lacroix, A | 1 |
| Caron, P | 1 |
| Bourdeau, I | 1 |
| Russo, M | 1 |
| Scollo, C | 1 |
| Pellegriti, G | 1 |
| Cotta, OR | 1 |
| Squatrito, S | 1 |
| Frasca, F | 1 |
| Cannavò, S | 1 |
| Gullo, D | 1 |
| Daffara, F | 1 |
| De Francia, S | 1 |
| Reimondo, G | 1 |
| Zaggia, B | 1 |
| Aroasio, E | 1 |
| Porpiglia, F | 1 |
| Volante, M | 1 |
| Termine, A | 1 |
| Di Carlo, F | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Berruti, A | 1 |
| Terzolo, M | 1 |
| Swinney, GR | 1 |
| Malik, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma[NCT05344027] | 35 participants (Actual) | Observational | 2022-04-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitotane and Hypothyroidism
| Article | Year |
|---|---|
Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Hypothy | 2023 |
3 other studies available for mitotane and Hypothyroidism
| Article | Year |
|---|---|
Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Female; Humans; Hypothyroidi | 2016 |
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Chromatogr | 2008 |
Intermittent heart block in a lethargic dog.
Topics: Adrenocortical Hyperfunction; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Electrocardiog | 1998 |